

ITCC-P4 International Workshop

IMPROVING PEDIATRIC ONCOLOGY DRUG DEVELOPMENT THROUGH PRECLINICAL RESEARCH 2018

Breakout Session:
Define the potential and use of other models than PDXs

Moderators:

David Shields (Pfizer, New York, USA)

Olaf Witt (KITZ, Heidelberg, Germany)



	PROs for improving clinical predictability	Other comments	Recommendation (mandatory/recommended /optional)
Organoids	<ul style="list-style-type: none"> screening of larger compound panels in a relevant in vitro model (Indication before mouse PDX model) 	<ul style="list-style-type: none"> Reproducibility across labs in adults Technical issue: generally working in kids (stem cell based) 	<ul style="list-style-type: none"> tbd Complementar in selected entities with lack of sufficient numbers of PDX mouse models
Zebrafish	<ul style="list-style-type: none"> Adult fish: good metastasis/angiogenesis model GEMM Fish: MoA/on target activity model 	<ul style="list-style-type: none"> Technical issues: larvae vs adult fish, sufficient tumor growth 	<ul style="list-style-type: none"> tbd Promising, but translatability to be investigated
Non brain orthotopic models	<ul style="list-style-type: none"> Reflects niche, supports metastasis ? (NB) 	<ul style="list-style-type: none"> Take rate better in PDX modelling 	<ul style="list-style-type: none"> tbd Model optimizing still required
Metastatic models	<ul style="list-style-type: none"> In general: more models needed: mets main reason for death MoA dependent (prevention of mets?) Caution: EWS/Fli1: promotes mets if hit to weak 	<ul style="list-style-type: none"> No evidence of clinical predictability yet Look more deeply into existing models Technical issue for CROs: reproducibility 	<ul style="list-style-type: none"> Recommended if model available (i.e. strong MoA)
Other?	<ul style="list-style-type: none"> Large models: e.g. sarcoma: endogenous tumors in dogs/pigs 2D/3D models Thick slice/organotypic CAMs 		<ul style="list-style-type: none"> Anna-Lisa: pigs mandatory